Parenteral iron use in the management of anemia in end-stage renal disease patients

Bailie, George R.; Johnson, Curtis A.; Mason, Nancy A.

doi:10.1016/s0272-6386(00)70294-0

Cited by 109 publications

(60 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Nevertheless, life-threatening and other adverse drug events are less frequent and less severe with the use of nondextran iron formulations. Iron sucrose carries probably the lowest risk for hypersensitivity reactions (131,132). The anaphylactoid reactions involving hypotension, dyspnea, back pain, flushing, and anxiety are predominantly to dextran (133).…”

Section: Evaluation Of Various Iron Preparationsmentioning

confidence: 99%

Clinical Aspects of Iron Use in the Anemia of Kidney Disease

Hörl¹

2007

Journal of the American Society of Nephrology

129

View full text Add to dashboard Cite

Section: Evaluation Of Various Iron Preparationsmentioning

confidence: 99%

Clinical Aspects of Iron Use in the Anemia of Kidney Disease

Hörl¹

2007

Journal of the American Society of Nephrology

129

View full text Add to dashboard Cite

“…Iron deficiency is common in haemodialysis patients and limits the efficacy of treatment with epoetin [1]. Intravenous iron therapy is, therefore, required by almost all haemodialysis patients receiving epoetin to achieve the target haemoglobin in the most efficient way [2,3].…”

Section: Introductionmentioning

confidence: 99%

Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients

Schiesser¹,

Binet²,

Tsinalis³

et al. 2006

Nephrology Dialysis Transplantation

View full text Add to dashboard Cite

Background. Haemodialysis patients need sustained treatment with intravenous iron because iron deficiency limits the efficacy of recombinant human epoetin therapy in these patients. However, the optimal intravenous iron maintenance dose has not been established yet. Methods. We performed a prospective multicentre clinical trial in iron-replete haemodialysis patients to evaluate the efficacy of weekly low-dose (50 mg) intravenous iron sucrose administration for 6 months to maintain the iron status, and to examine the effect on epoetin dosage needed to maintain stable haemoglobin values in these patients. Fifty patients were enrolled in this prospective, open-label, single arm, phase IV study. Results. Forty-two patients (84%) completed the study. After 6 months of intravenous iron sucrose treatment, the mean ferritin value showed a tendency to increase slightly from 405 AE 159 at baseline to 490 AE 275 mg/l at the end of the study, but iron, transferrin levels and transferrin saturation did not change. The haemoglobin level remained stable (12 AE 1.1 at baseline and 12.1 AE 1.5 g/dl at the end of the study). The mean dose of darbepoetin alfa could be reduced from 0.75 to 0.46 mg/kg/week; epoetin alfa was decreased from 101 to 74 IU/kg/week; and the mean dose of epoetin beta could be reduced from 148 to 131 IU/kg/week at the end of treatment. Conclusions. A regular 50 mg weekly dosing schedule of iron sucrose maintains stable iron stores and haemoglobin levels in haemodialysed patients and allows considerable dose reductions for epoetins. Low-dose intravenous iron therapy may represent an optimal approach to treat the continuous loss of iron in dialysis patients.

show abstract

“…52 Ferric gluconate and iron sucrose may also be safe among patients who are allergic to or intolerant of iron dextran. 40,55,56,107 Clinical data, however, are conflicting in the association between iron and infection. Oxidative stress should not be considered as barrier to administration of continued intravenous iron.…”

Section: Resultsmentioning

confidence: 99%

“…Oxidative stress should not be considered as barrier to administration of continued intravenous iron. 107 Current evidence on the role between intravenous iron in increasing the incidence of infection and oxidative stress deserves special consideration. Erythropoietin therapy decreases the incidence of iron overload as compared to no erythropoietin therapy.…”

Section: Resultsmentioning

confidence: 99%

Safety Issues With Intravenous Iron Products in the Management of Anemia in Chronic Kidney Disease

Hayat¹

2008

Clinical Medicine & Research

View full text Add to dashboard Cite

Parenteral iron use in the management of anemia in end-stage renal disease patients

Cited by 109 publications

References 35 publications

Clinical Aspects of Iron Use in the Anemia of Kidney Disease

Clinical Aspects of Iron Use in the Anemia of Kidney Disease

Weekly low-dose treatment with intravenous iron sucrose maintains iron status and decreases epoetin requirement in iron-replete haemodialysis patients

Safety Issues With Intravenous Iron Products in the Management of Anemia in Chronic Kidney Disease

Contact Info

Product

Resources

About